modelN06AX02
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Tryptophan | |
| ATC code: | N06AX02 | route: | oral |
| compartments: | 1 | |
| dosage: | 2000 | mg |
| volume of distribution: | 27 | L |
| clearance: | 1.8 | L/h |
| other parameters in model implementation | ||
Tryptophan is an essential amino acid used as a dietary supplement and formerly as an antidepressant or sleep aid. It is a precursor for serotonin and melatonin biosynthesis. Its use as a drug has declined due to safety concerns related to eosinophilia–myalgia syndrome in contaminated batches. It is not widely approved as a prescription medication today but is available as a supplement.
Pharmacokinetics
Pharmacokinetic parameters for oral L-tryptophan (dose: 2 g) in healthy adult volunteers.
References
Lalanne, S, et al., & Tordjman, S (2021). Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder. International journal of molecular sciences 22(3) –. DOI:10.3390/ijms22031490 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33540815
Nøhr, MK, et al., & Nielsen, CU (2015). Is oral absorption of vigabatrin carrier-mediated?. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 69 10–18. DOI:10.1016/j.ejps.2014.12.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25562534
Kumar, S, et al., & Mautino, MR (2020). Discovery of indoximod prodrugs and characterization of clinical candidate NLG802. European journal of medicinal chemistry 198 112373–None. DOI:10.1016/j.ejmech.2020.112373 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32422549
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)